Intensity-modulated salvage radiotherapy with simultaneous integrated boost for local recurrence of prostate carcinoma: a pilot study on the place of PET-choline for guiding target volume delineation

Imaging for the Detection of Locoregional Recurrences in Biochemical Progression After Radical Prostatectomy—A Systematic Review

“…This is an important issue, since the pattern of treatment failure after RP is predominantly local, with a relatively low risk of metastatic failure (16%) [3]. Coupled with the encouraging results of early SRT for BCR PCa and a dose-response relationship that indicates a possible benefit of using higher radiation doses, proper identification of lesions could translate into significant clinical gains [42,43]. In the event that either MRI or PET would detect bone metastasis, the patient would get palliative treatment and not be considered for salvage treatment.…”

18F-FLT and 18F-FDG PET/CT in Predicting Response to Chemoradiotherapy in Nasopharyngeal Carcinoma: Preliminary Results

“…And International Atomic Energy Agency (IAEA) has formally recommended to use FDG PET/CT for the purposes of radiotherapy target volume delineation (TVD) for curative intent treatment of NSCLC42. Similar use of PET/CT has been applied in prostate and rectal cancer4344. In HNC, PET-planning has been confirmed that it translated into smaller GTV, CTV and PTV for the primary tumor volumes, and also demonstrated an improvement on dosimetry by lowering dose to certain organs at risk (OAR)45.…”

ESTRO ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy

“…In fact, a recent search on https://www.clinicatrials.gov only identified NCT05328505 and NCT01411345. At the moment, the clinical experience is also limited and mostly retrospective [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] . A similar approach was used in the recent phase 2, dual-center, open-label, single-arm SCIMITAR trial, testing extreme hypofractionation in patients with biochemical and/or clinical relapse [45] .…”